Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single and Multiple Ascending Dose Study of JNJ-67953964 in Healthy Japanese Men
jRCT2071210010Phase 1Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing JNJ-67953964 with Placebo (2 arms). Primary endpoints: Number of participants with adverse events (single-dose cohort), Number of participants with adverse events (multiple-dose cohort) and 2 more. Started May 2021; status: active, not recruiting.
02
Drugs
aticaprant
Beyond the preview
Go deeper on jRCT2071210010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071210010.